Renaud La Joie

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8417295/publications.pdf

Version: 2024-02-01

47409 46524 10,324 134 49 93 citations h-index g-index papers 144 144 144 10666 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Quantification of amyloid beta and tau PET without a structural MRI. Alzheimer's and Dementia, 2023, 19, 444-455.	0.4	7
2	The Rapid Naming Test: Development and initial validation in typically aging adults. Clinical Neuropsychologist, 2022, 36, 1822-1843.	1.5	7
3	Cortical hypometabolism reflects local atrophy and tau pathology in symptomatic Alzheimer's disease. Brain, 2022, 145, 713-728.	3.7	43
4	rPOP: Robust PET-only processing of community acquired heterogeneous amyloid-PET data. Neurolmage, 2022, 246, 118775.	2.1	17
5	Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration. Neurology, 2022, 98, .	1.5	49
6	Dissecting the clinical heterogeneity of early-onset Alzheimer's disease. Molecular Psychiatry, 2022, 27, 2674-2688.	4.1	40
7	Regional Aβ-tau interactions promote onset and acceleration of Alzheimer's disease tau spreading. Neuron, 2022, 110, 1932-1943.e5.	3.8	64
8	Diagnostic Accuracy of Magnetic Resonance Imaging Measures of Brain Atrophy Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Degeneration. JAMA Network Open, 2022, 5, e229588.	2.8	18
9	Multi-Modal Biomarkers of Repetitive Head Impacts and Traumatic Encephalopathy Syndrome: A Clinicopathological Case Series. Journal of Neurotrauma, 2022, 39, 1195-1213.	1.7	16
10	Plasma P-tau181 and P-tau217 in Patients With Traumatic Encephalopathy Syndrome With and Without Evidence of Alzheimer Disease Pathology. Neurology, 2022, 99, .	1.5	10
11	Tau Beats Amyloid in Predicting Brain Atrophy in Alzheimer Disease: Implications for Prognosis and Clinical Trials. Journal of Nuclear Medicine, 2022, 63, 830-832.	2.8	7
12	Imaging Alzheimer's pathology stage by stage. Nature Aging, 2022, 2, 465-467.	5.3	1
13	Cerebral amyloid angiopathy interacts with neuritic amyloid plaques to promote tau and cognitive decline. Brain, 2022, 145, 2823-2833.	3.7	22
14	Amyloid, tau and metabolic PET correlates of cognition in early and late-onset Alzheimer's disease. Brain, 2022, 145, 4489-4505.	3.7	23
15	Association of <i>APOE4</i> and Clinical Variability in Alzheimer Disease With the Pattern of Tau- and Amyloid-PET. Neurology, 2021, 96, e650-e661.	1.5	73
16	Worth the Wait: Delayed Recall after 1 Week Predicts Cognitive and Medial Temporal Lobe Trajectories in Older Adults. Journal of the International Neuropsychological Society, 2021, 27, 382-388.	1.2	3
17	Hippocampal subfield volumetry from structural isotropic 1 mm ³ <scp>MRI</scp> scans: A note of caution. Human Brain Mapping, 2021, 42, 539-550.	1.9	84
18	Association Between Ambient Air Pollution and Amyloid Positron Emission Tomography Positivity in Older Adults With Cognitive Impairment. JAMA Neurology, 2021, 78, 197.	4.5	54

#	Article	IF	Citations
19	Diagnostic Accuracy of Amyloid versus ¹⁸ Fâ€Fluorodeoxyglucose Positron Emission Tomography in <scp>Autopsyâ€Confirmed</scp> Dementia. Annals of Neurology, 2021, 89, 389-401.	2.8	34
20	The impact of demographic, clinical, genetic, and imaging variables on tau PET status. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2245-2258.	3.3	27
21	Spatial Relationships between Molecular Pathology and Neurodegeneration in the Alzheimer's Disease Continuum. Cerebral Cortex, 2021, 31, 1-14.	1.6	34
22	Association of remote mild traumatic brain injury with cortical amyloid burden in clinically normal older adults. Brain Imaging and Behavior, 2021, 15, 2417-2425.	1.1	9
23	Detecting Alzheimer's disease biomarkers with a brief tablet-based cognitive battery: sensitivity to Aβ and tau PET. Alzheimer's Research and Therapy, 2021, 13, 36.	3.0	10
24	Crossed cerebellar diaschisis on ¹⁸ F-FDG PET: Frequency across neurodegenerative syndromes and association with ¹¹ C-PIB and ¹⁸ F-Flortaucipir. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 2329-2343.	2.4	9
25	Comorbid neuropathological diagnoses in early versus late-onset Alzheimer's disease. Brain, 2021, 144, 2186-2198.	3.7	100
26	Neuroimaging in Frontotemporal Dementia: Heterogeneity and Relationships with Underlying Neuropathology. Neurotherapeutics, 2021, 18, 728-752.	2.1	30
27	Four distinct trajectories of tau deposition identified in Alzheimer's disease. Nature Medicine, 2021, 27, 871-881.	15.2	354
28	Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 872-880.	0.9	17
29	A multicenter comparison of [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis. European Journal of Nuclear Medicine and Molecular lmaging, 2021, 48, 2295-2305.	3.3	41
30	Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease. JAMA Neurology, 2021, 78, 961.	4.5	148
31	Multimodal neuroimaging of sex differences in cognitively impaired patients on the Alzheimer's continuum: greater tau-PET retention in females. Neurobiology of Aging, 2021, 105, 86-98.	1.5	29
32	Effect of the Histone Deacetylase Inhibitor FRM-0334 on Progranulin Levels in Patients With Progranulin Gene Haploinsufficiency. JAMA Network Open, 2021, 4, e2125584.	2.8	18
33	Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurology, The, 2021, 20, 739-752.	4.9	220
34	Fusiform gyrus phosphoâ€ŧau is associated with failure of proper name retrieval in aging. Annals of Neurology, 2021, 90, 988-993.	2.8	4
35	Social Behavior Observer Checklist: Patterns of Spontaneous Behaviors Differentiate Patients With Neurodegenerative Disease From Healthy Older Adults. Frontiers in Neurology, 2021, 12, 683162.	1.1	6
36	Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2259-2271.	3.3	10

#	Article	lF	CITATIONS
37	Plasma Tau and Neurofilament Light in Frontotemporal Lobar Degeneration and Alzheimer Disease. Neurology, 2021, 96, e671-e683.	1.5	84
38	The many dimensions of human hippocampal organization and (dys)function. Trends in Neurosciences, 2021, 44, 977-989.	4.2	57
39	Distinct tau PET patterns in atrophyâ€defined subtypes of Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, 335-344.	0.4	73
40	Spatial patterns of tau deposition are associated with amyloid, ApoE, sex, and cognitive decline in older adults. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2155-2164.	3.3	20
41	Plasma biomarkers of astrocytic and neuronal dysfunction in early―and lateâ€onset Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, 681-695.	0.4	143
42	Association of Cognitive and Behavioral Features Between Adults With Tuberous Sclerosis and Frontotemporal Dementia. JAMA Neurology, 2020, 77, 358.	4.5	14
43	Prospective longitudinal atrophy in Alzheimer's disease correlates with the intensity and topography of baseline tau-PET. Science Translational Medicine, 2020, 12, .	5.8	353
44	Tau Positron Emission Tomographic Findings in a Former US Football Player With Pathologically Confirmed Chronic Traumatic Encephalopathy. JAMA Neurology, 2020, 77, 517.	4.5	43
45	Latent atrophy factors related to phenotypical variants of posterior cortical atrophy. Neurology, 2020, 95, e1672-e1685.	1.5	19
46	Investigating the clinico-anatomical dissociation in the behavioral variant of Alzheimer disease. Alzheimer's Research and Therapy, 2020, 12, 148.	3.0	17
47	BHAâ€CS: A novel cognitive composite for Alzheimer's disease and related disorders. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12042.	1.2	12
48	Plasma Glial Fibrillary Acidic Protein Levels Differ Along the Spectra of Amyloid Burden and Clinical Disease Stage1. Journal of Alzheimer's Disease, 2020, 78, 265-276.	1.2	43
49	Normalization of CSF pTau measurement by AÎ ² 40 improves its performance as a biomarker of Alzheimer's disease. Alzheimer's Research and Therapy, 2020, 12, 97.	3.0	31
50	How †atypical†is the neuroimaging signature of Alzheimer†satypical variants? MRI and PET imaging of posterior cortical atrophy and logopenic variant of primary progressive aphasia. Alzheimer's and Dementia, 2020, 16, e040623.	0.4	0
51	The development of a valid, reliable, harmonized segmentation protocol for hippocampal subfields and medial temporal lobe cortices: A progress update. Alzheimer's and Dementia, 2020, 16, e046652.	0.4	2
52	Evaluation of a visual interpretation method for tauâ€PET with ¹⁸ Fâ€flortaucipir. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12133.	1.2	17
53	18F-flortaucipir PET to autopsy comparisons in Alzheimer's disease and other neurodegenerative diseases. Brain, 2020, 143, 3477-3494.	3.7	100
54	Temporal variant of frontotemporal dementia in C9orf72 repeat expansion carriers: two case studies. Brain Imaging and Behavior, 2020, 14, 336-345.	1.1	3

#	Article	IF	CITATIONS
55	Assessment of Demographic, Genetic, and Imaging Variables Associated With Brain Resilience and Cognitive Resilience to Pathological Tau in Patients With Alzheimer Disease. JAMA Neurology, 2020, 77, 632.	4.5	80
56	Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration. Nature Medicine, 2020, 26, 387-397.	15.2	471
57	A molecular gradient along the longitudinal axis of the human hippocampus informs large-scale behavioral systems. Nature Communications, 2020, 11, 960.	5.8	100
58	Morphometric network differences in ageing versus Alzheimer's disease dementia. Brain, 2020, 143, 635-649.	3.7	37
59	An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. Nature Reviews Neurology, 2020, 16, 265-284.	4.9	121
60	Sex-related differences in the relationship between \hat{l}^2 -amyloid and cognitive trajectories in older adults Neuropsychology, 2020, 34, 835-850.	1.0	9
61	Distinct Interplay Between Atrophy and Hypometabolism in Alzheimer's Versus Semantic Dementia. Cerebral Cortex, 2019, 29, 1889-1899.	1.6	24
62	Cross-sectional and longitudinal characterization of SCD patients recruited from the community versus from a memory clinic: subjective cognitive decline, psychoaffective factors, cognitive performances, and atrophy progression over time. Alzheimer's Research and Therapy, 2019, 11, 61.	3.0	30
63	Progress update from the hippocampal subfields group. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 439-449.	1.2	34
64	Tau PET and multimodal brain imaging in patients at risk for chronic traumatic encephalopathy. Neurolmage: Clinical, 2019, 24, 102025.	1.4	53
65	Cortical developmental abnormalities in logopenic variant primary progressive aphasia with dyslexia. Brain Communications, 2019, 1, fcz027.	1.5	11
66	Is there a specific memory signature associated with \hat{A}^2 -PET positivity in patients with amnestic mild cognitive impairment?. Neurobiology of Aging, 2019, 77, 94-103.	1.5	9
67	Alzheimer's pathology targets distinct memory networks in the ageing brain. Brain, 2019, 142, 2492-2509.	3.7	131
68	An Opioid-Related Amnestic Syndrome With Persistent Effects on Hippocampal Structure and Function. Journal of Neuropsychiatry and Clinical Neurosciences, 2019, 31, 392-396.	0.9	16
69	Medial Temporal Lobe Disconnection and Hyperexcitability Across Alzheimer's Disease Stages. Journal of Alzheimer's Disease Reports, 2019, 3, 103-112.	1.2	48
70	Tau covariance patterns in Alzheimer's disease patients match intrinsic connectivity networks in the healthy brain. NeuroImage: Clinical, 2019, 23, 101848.	1.4	73
71	Atypical clinical features associated with mixed pathology in a case of non-fluent variant primary progressive aphasia. Neurocase, 2019, 25, 39-47.	0.2	8
72	Effect of Off-Target Binding on ¹⁸ F-Flortaucipir Variability in Healthy Controls Across the Life Span. Journal of Nuclear Medicine, 2019, 60, 1444-1451.	2.8	96

#	Article	IF	Citations
73	Longitudinal tau accumulation and atrophy in aging and alzheimer disease. Annals of Neurology, 2019, 85, 229-240.	2.8	198
74	Multisite study of the relationships between <i>antemortem</i> [¹¹ C]PIBâ€PET Centiloid values and <i>postmortem</i> measures of Alzheimer's disease neuropathology. Alzheimer's and Dementia, 2019, 15, 205-216.	0.4	155
75	Brain properties predict proximity to symptom onset in sporadic Alzheimer's disease. Brain, 2018, 141, 1871-1883.	3.7	43
76	Associations between [¹⁸ F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample. Neurology, 2018, 90, e282-e290.	1.5	113
77	Regional patterns of gray matter volume, hypometabolism, and beta-amyloid in groups at risk of Alzheimer's disease. Neurobiology of Aging, 2018, 63, 140-151.	1.5	30
78	F1â€01â€02: NONâ€AMNESTIC PHENOTYPES OF ALZHEIMER'S DISEASE, EARLY AGE OF ONSET AND <i>APOE</i> GENOTYPE ARE ASSOCIATED WITH TAUâ€, NOT Aβâ€PET. Alzheimer's and Dementia, 2018, 14, P199.	0.4	0
79	ICâ€Pâ€145: NONâ€AMNESTIC PHENOTYPES OF ALZHEIMER'S DISEASE, EARLY AGE OF ONSET AND APOE GENOTARE ASSOCIATED WITH TAU, NOT Aβâ€PET. Alzheimer's and Dementia, 2018, 14, P123.	TYPE 0.4	O
80	Discriminative Accuracy of [¹⁸ F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA - Journal of the American Medical Association, 2018, 320, 1151.	3.8	298
81	Superior explicit memory despite severe developmental amnesia: Inâ€depth case study and neural correlates. Hippocampus, 2018, 28, 867-885.	0.9	14
82	Elevated ¹⁸ F-AV-1451 PET tracer uptake detected in incidental imaging findings. Neurology, 2017, 88, 1095-1097.	1.5	38
83	Distinct white matter injury associated with medial temporal lobe atrophy in Alzheimer's versus semantic dementia. Human Brain Mapping, 2017, 38, 1791-1800.	1.9	26
84	Subjective cognitive decline and \hat{l}^2 -amyloid burden predict cognitive change in healthy elderly. Neurology, 2017, 89, 2002-2009.	1.5	53
85	Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease. Brain, 2017, 140, 3286-3300.	3.7	472
86	Association between educational attainment and amyloid deposition across the spectrum from normal cognition to dementia: neuroimaging evidence for protection and compensation. Neurobiology of Aging, 2017, 59, 72-79.	1.5	60
87	A harmonized segmentation protocol for hippocampal and parahippocampal subregions: Why do we need one and what are the key goals?. Hippocampus, 2017, 27, 3-11.	0.9	130
88	Subjective cognitive decline in cognitively normal elders from the community or from a memory clinic: Differential affective and imaging correlates. Alzheimer's and Dementia, 2017, 13, 550-560.	0.4	135
89	[P1–031]: DOES APOEâ€Îµ4 HAVE AN Aβâ€INDEPENDENT EFFECT ON TAU PATHOLOGY? NEUROIMAGING INVESTIGATIONS IN COGNITIVELY NORMAL ELDERS AND PATIENTS WITH ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P245.	0.4	O
90	[P2â€"373]: AV1451â€PET CORTICAL UPTAKE AND REGIONAL DISTRIBUTION PREDICT LONGITUDINAL ATROPHY ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P769.	IN 0.4	3

#	Article	IF	Citations
91	[ICâ€Pâ€059]: DOES APOEâ€Îµ4 HAVE AN Aβâ€INDEPENDENT EFFECT ON TAU PATHOLOGY? NEUROIMAGING INVESTIGATIONS IN COGNITIVELY NORMAL ELDERS AND PATIENTS WITH ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P48.	0.4	O
92	[ICâ€Pâ€186]: AV1451â€PET UPTAKE AND CSF BIOMARKERS IN A HETEROGENEOUS CLINICAL SAMPLE: TWO SID THE SAME COIN?. Alzheimer's and Dementia, 2017, 13, P137.	ES OF 0.4	0
93	[ICâ€01–01]: AV1451â€PET CORTICAL UPTAKE AND REGIONAL DISTRIBUTION PREDICTS LONGITUDINAL ATROI ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P1.	PHY IN 0.4	O
94	[P1â€"414]: DOES APOE ε4 HAVE AN Aβâ€INDEPENDENT EFFECT ON TAU PATHOLOGY? NEUROIMAGING INVESTIGATIONS IN COGNITIVELY NORMAL ELDERS AND PATIENTS WITH ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P435.	0.4	О
95	[O3–O3–O4]: AV1451â€PET UPTAKE AND CSF BIOMARKERS IN A HETEROGENEOUS CLINICAL SAMPLE: TWO OF THE SAME COIN?. Alzheimer's and Dementia, 2017, 13, P904.	SIDES 0.4	O
96	Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease. NeuroImage, 2017, 157, 448-463.	2.1	341
97	Qualitative and quantitative assessment of selfâ€reported cognitive difficulties in nondemented elders: Association with medical help seeking, cognitive deficits, and I²â€amyloid imaging. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 5, 23-34.	1.2	47
98	ICâ€Pâ€149: Qualiâ€Quantitative Assessment of Selfâ€Reported Cognitive Difficulties in Nonâ€Demented Elders: Relationships With Medical Help Seeking, Cognition and Neuroimaging Biomarkers. Alzheimer's and Dementia, 2016, 12, P110.	0.4	O
99	ICIâ€01â€01: What Have We Learned?. Alzheimer's and Dementia, 2016, 12, P12.	0.4	O
100	P2â€343: Qualiâ€Quantitative Assessment of Selfâ€Reported Cognitive Difficulties in Nonâ€Demented Elders: Relationships with Medical Help Seeking, Cognition and Neuroimaging Biomarkers. Alzheimer's and Dementia, 2016, 12, P774.	0.4	O
101	Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's disease. Brain, 2016, 139, 2528-2539.	3.7	58
102	Hippocampal Subfield Volumetry and 3D Surface Mapping in Subjective Cognitive Decline. Journal of Alzheimer's Disease, 2015, 48, S141-S150.	1.2	102
103	Anosognosia in Alzheimer disease: Disconnection between memory and selfâ€related brain networks. Annals of Neurology, 2015, 78, 477-486.	2.8	84
104	Are AD-Typical Regions the Convergence Point of Multiple Pathologies?. Frontiers in Aging Neuroscience, 2015, 7, 42.	1.7	16
105	Why musical memory can be preserved in advanced Alzheimer's disease. Brain, 2015, 138, 2438-2450.	3.7	214
106	Atrophy patterns in early clinical stages across distinct phenotypes of <scp>A</scp> lzheimer's disease. Human Brain Mapping, 2015, 36, 4421-4437.	1.9	196
107	Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. Brain, 2015, 138, 2020-2033.	3.7	319
108	Effects of age and Alzheimer's disease on hippocampal subfields. Human Brain Mapping, 2015, 36, 463-474.	1.9	130

#	Article	IF	CITATIONS
109	Quantitative comparison of 21 protocols for labeling hippocampal subfields and parahippocampal subregions in in vivo MRI: Towards a harmonized segmentation protocol. NeuroImage, 2015, 111, 526-541.	2.1	284
110	The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features. Brain, 2015, 138, 2732-2749.	3.7	397
111	Cognitive and Brain Profiles Associated with Current Neuroimaging Biomarkers of Preclinical Alzheimer's Disease. Journal of Neuroscience, 2015, 35, 10402-10411.	1.7	117
112	Structural imaging of hippocampal subfields in healthy aging and Alzheimer's disease. Neuroscience, 2015, 309, 29-50.	1.1	265
113	FDG-PET Contributions to the Pathophysiology of Memory Impairment. Neuropsychology Review, 2015, 25, 326-355.	2.5	23
114	Toward a Better Understanding of the Injured Hippocampus: Multimodal Imaging in Functionally Relevant Substructures. Journal of Neuroscience, 2014, 34, 10793-10794.	1.7	3
115	Gene-Environment Interactions: Lifetime Cognitive Activity, APOE Genotype, and Beta-Amyloid Burden. Journal of Neuroscience, 2014, 34, 8612-8617.	1.7	107
116	Imaging Brain Effects of APOE4 in Cognitively Normal Individuals Across the Lifespan. Neuropsychology Review, 2014, 24, 290-299.	2.5	67
117	Intrinsic Connectivity Identifies the Hippocampus as a Main Crossroad between Alzheimer's and Semantic Dementia-Targeted Networks. Neuron, 2014, 81, 1417-1428.	3.8	148
118	IC-P-093: EFFECTS OF AGE AND ALZHEIMER'S DISEASE ON HIPPOCAMPAL SUBFIELDS: COMPARISON BETWEEN MANUAL AND FREESURFER VOLUMETRY. , 2014, 10, P52-P53.		0
119	P1-212: THE USE OF NEUROIMAGING BIOMARKERS IN PRECLINICAL ALZHEIMER'S DISEASE. , 2014, 10, P380-P38	1.	0
120	IC-02-03: EXISTING THRESHOLDS FOR PIB POSITIVITY ARE TOO HIGH. , 2014, 10, P4-P5.		1
121	P1-297: EFFECTS OF AGE AND ALZHEIMER'S DISEASE ON HIPPOCAMPAL SUBFIELDS: COMPARISON BETWEEN MANUAL AND FREESURFER VOLUMETRY. , 2014, 10, P420-P420.		0
122	IC-02-02: THE USE OF NEUROIMAGING BIOMARKERS IN PRECLINICAL ALZHEIMER'S DISEASE. , 2014, 10, P4-P4.		0
123	O3-10-02: LIFETIME COGNITIVE ACTIVITY, APOLIPOPROTEIN E GENOTYPE, AND BRAIN BETA-AMYLOID. , 2014, 10, P228-P228.		1
124	Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease. Neurolmage: Clinical, 2013, 2, 356-365.	1.4	297
125	Relationships between years of education and gray matter volume, metabolism and functional connectivity in healthy elders. Neurolmage, 2013, 83, 450-457.	2.1	234
126	Age effect on the default mode network, inner thoughts, and cognitive abilities. Neurobiology of Aging, 2013, 34, 1292-1301.	1.5	114

#	Article	lF	CITATIONS
127	Readiness to change and brain damage in patients with chronic alcoholism. Psychiatry Research - Neuroimaging, 2013, 213, 202-209.	0.9	34
128	Hippocampal subfield volumetry in mild cognitive impairment, Alzheimer's disease and semantic dementia. NeuroImage: Clinical, 2013, 3, 155-162.	1.4	219
129	Region-Specific Hierarchy between Atrophy, Hypometabolism, and \hat{l}^2 -Amyloid ($\hat{Al^2}$) Load in Alzheimer's Disease Dementia. Journal of Neuroscience, 2012, 32, 16265-16273.	1.7	319
130	Role of hippocampal CA1 atrophy in memory encoding deficits in amnestic Mild Cognitive Impairment. Neurolmage, 2012, 59, 3309-3315.	2.1	42
131	The Hippocampus Remains Activated over the Long Term for the Retrieval of Truly Episodic Memories. PLoS ONE, 2012, 7, e43495.	1.1	52
132	When Music and Long-Term Memory Interact: Effects of Musical Expertise on Functional and Structural Plasticity in the Hippocampus. PLoS ONE, 2010, 5, e13225.	1.1	99
133	Differential effect of age on hippocampal subfields assessed using a new high-resolution 3T MR sequence. Neurolmage, 2010, 53, 506-514.	2.1	149
134	Altered excitatory and inhibitory neuronal subpopulation parameters are distinctly associated with tau and amyloid in Alzheimer's disease. ELife, 0, 11, .	2.8	45